Xtl Biopharmaceuticals (XTLB) Net Cash Flow Growth (3y) (2012 - 2016)
Xtl Biopharmaceuticals (XTLB) Net Cash Flow Growth (3y) (2012 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 8.51% |
| Dec 31, 2015 | 77.39% |
| Sep 30, 2015 | -99.70% |
| Jun 30, 2015 | 52.85% |
| Dec 31, 2014 | 40.63% |
| Sep 30, 2014 | -46.82% |
| Jun 30, 2014 | 29.74% |
| Mar 31, 2014 | 16.52% |
| Dec 31, 2013 | -58.78% |
| Sep 30, 2013 | 36.46% |
| Jun 30, 2013 | -79.74% |
| Mar 31, 2013 | 36.10% |
| Dec 31, 2012 | -68.15% |
| Sep 30, 2012 | 32.46% |
| Jun 30, 2012 | -156.73% |
| Mar 31, 2012 | 75.14% |